DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (MURA) (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies ...
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (MURA) (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered ...
Nemvaleukin alfa (nemvaleukin) is a novel, engineered cytokine designed to leverage antitumor effects of the IL-2 pathway while mitigating its hallmark toxicities that limit its use. Nemvaleukin ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果